Combined anti-leukemic effect of gilteritinib and GSK-J4 in FLT3-ITD+ acute myeloid leukemia
Gilteritinib treats acute myeloid leukemia (AML) with the FMS-like receptor tyrosine kinase-3 (FLT3) internal tandem duplication (ITD) mutation. Dysregulation of histone modification affects the genesis and progression of AML. Strategies targeting key histone regulators have not been applied to the...
Saved in:
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-02-01
|
Series: | Translational Oncology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523325000026 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|